openPR Logo
Press release

Omen Kaine Reimagines Poe's Madness in Bold New Theater Play, The Heart Tells Tales

07-30-2025 09:08 PM CET | Leisure, Entertainment, Miscellaneous

Press release from: ABNewswire

Omen Kaine Reimagines Poe's Madness in Bold New Theater Play,

A dark, pandemic-era thriller blending psychological drama, live experimental music, and the haunting spirit of Edgar Allan Poe.
Los Angeles, CA, USA - July 30, 2025 - Prepare to be haunted in a whole new way. This fall, acclaimed playwright Omen Kaine unveils The Heart Tells Tales, a gripping, genre-defying adaptation inspired by Edgar Allan Poe's The Tell-Tale Heart. Set against the eerie silence of pandemic-era Boston, the play dares to look deeper into the psychological toll of caregiving, isolation, and suppressed trauma.

The Heart Tells Tales is the second chapter in Kaine's visionary Through the Altered Lens Trilogy-and this installment does not hold back. The story begins when neighbors of a revered, old-school musician report bloodcurdling screams. Police discover a horrifying crime scene-what appears to be domestic violence. But this is no marital dispute: the culprit is a young caregiver who confesses to murdering the older musician in his care. While the case seems open and shut, something doesn't quite add up. The truth, like Poe's original tale, may be more twisted than anyone can imagine.

Image: https://www.abnewswire.com/upload/2025/07/7cce9ed90c4a4c157f6325b480cb7697.jpg

Blending gritty storytelling with live original music, the production features an electrifying score by The Clandestine Circle Quintet, an experimental Los Angeles-based group whose sound fuses hip hop, rock, and jazz. The music doesn't just underscore the narrative-it becomes part of its pulse, intensifying the suspense as the plot unfolds.

Hi Fi Underground is the production company bringing this powerful story to life. The company is dedicated to producing the theatrical works of Omen Kaine, a boundary-pushing voice in modern theater. For a short time, Kaine lived in a part of South Central L.A. known as the Jungle. On February 9, 1971 at 6:01 AM PST, a devastating M6.6 earthquake struck the Los Angeles metro area. Shortly after, his family moved back to Boston, where Kaine spent much of his formative years. He later attended high school in Concord, Massachusetts, where the transcendentalists once roamed.

From the 1990s through the early 2000s, Kaine traveled the U.S. and abroad, creating music and visual art. He later studied the arts at New York University and published his first novella, A Darker Nature, in 2003. His second publication was the illustrated play/graphic novel That Bookstore in the Alley. His first theatrical production, Masoch and Desade, debuted on Theater Row in Los Angeles (2019) and later played in Brooklyn, New York (2022). Now, he returns with his latest and most ambitious work yet: The Heart Tells Tales.

Image: https://www.abnewswire.com/upload/2025/07/b7d9c7bef275b37f6bfd7993be581903.jpg

Produced by Hi Fi Underground Production, the show opens in Los Angeles October 23-25, 2025 at Skiptown Playhouse (665 Heliotrope Dr, Los Angeles, CA 90004), followed by a New York run November 21-23, 2025 at Under St. Marks Theater (94 Saint Marks Place, New York, NY 10009).

Tickets for the Los Angeles show are available now at:

https://www.eventbrite.com/e/the-heart-tells-tales-tickets-1543121069659

Tickets for the New York show are also available at:

https://www.eventbrite.com/e/the-heart-tells-tales-tickets-1474594123719

"This is not just a play. It's a reckoning," says Omen Kaine. "We're looking through the eyes of trauma, guilt, and the blurred lines of morality-and amplifying it with sound and soul."

An international tour stop in Belgium is also slated for winter 2026.

SHOW DATES & LOCATIONS

LOS ANGELES

Skiptown Playhouse

665 Heliotrope Dr, Los Angeles, CA 90004

October 23-25, 2025 | 7:30 PM - 10:00 PM PST

Purchase Tickets [https://www.eventbrite.com/e/the-heart-tells-tales-tickets-1543121069659]

NEW YORK CITY

Under St. Marks Theater

94 Saint Marks Place, New York, NY 10009

November 21-23, 2025 | 7:00 PM - 9:30 PM EST

Purchase Tickets [https://www.eventbrite.com/e/the-heart-tells-tales-tickets-1474594123719]

Follow updates and behind-the-scenes sneak peeks:

* Instagram @hifiundergroundshop : https://www.instagram.com/hifiundergroundshop

* Facebook: https://www.facebook.com/profile.php?id=100064267262382

For media inquiries, interviews, or press passes, please contact:

Domenick Nati

Nati Celebrity Services

DNati[at]NatiCelebs[dot]com

Media Contact
Company Name: Nati Celebrity Services, Inc.
Contact Person: Domenick Nati
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=omen-kaine-reimagines-poes-madness-in-bold-new-theater-play-the-heart-tells-tales]
Country: United States
Website: http://www.naticelebs.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Omen Kaine Reimagines Poe's Madness in Bold New Theater Play, The Heart Tells Tales here

News-ID: 4127120 • Views:

More Releases from ABNewswire

Myasthenia Gravis Market Expected to Witness Substantial Growth by 2034: Know Market Drivers and Opportunities for Healthcare Executives | DelveInsight
Myasthenia Gravis Market Expected to Witness Substantial Growth by 2034: Know Ma …
The Myasthenia Gravis treatment market is projected to experience significant expansion in the coming years, propelled by the development of innovative therapies from key myasthenia gravis companies including Horizon Therapeutics, Amgen, Janssen Research & Development, Hoffmann-La Roche, Immunovant Sciences GmbH, Alexion, AstraZeneca Rare Disease, Regeneron Pharmaceuticals, Kyverna Therapeutics, and Cartesian Therapeutics, among others. DelveInsight's "Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive insights into
Chronic Spontaneous Urticaria Treatment Landscape: FDA Approves RHAPSIDO, First Oral BTK Inhibitor | DelveInsight's Perspective on Market Impact, Competitive Landscape and Pipeline Therapies
Chronic Spontaneous Urticaria Treatment Landscape: FDA Approves RHAPSIDO, First …
DelveInsight's latest report highlights the transformative impact of the FDA's approval of RHAPSIDO (remibrutinib) by Novartis AG on September 30, 2025. This landmark approval marks the first oral Bruton tyrosine kinase (BTK) inhibitor specifically designed for chronic spontaneous urticaria, offering revolutionary hope for over 1.7 million patients in the United States suffering from this debilitating condition characterized by recurring hives and angioedema without identifiable triggers. Key Chronic Spontaneous Urticaria Market Highlights * RHAPSIDO's
FDA Approves Lurbinectedin + Atezolizumab: The first combination therapy for Extensive-Stage SCLC | Market Projections and Opportunities for Healthcare Executives | DelveInsight
FDA Approves Lurbinectedin + Atezolizumab: The first combination therapy for Ext …
The U.S. Food and Drug Administration's historic approval of lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) for maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) on October 2, 2025, represents a paradigm-shifting moment that will fundamentally transform the small cell lung cancer treatment market, according to DelveInsight Business Research LLP, a leading pharmaceutical market intelligence firm. This landmark FDA approval establishes the first combination therapy specifically designed for first-line maintenance
FDA's New ANDA Prioritization Pilot Signals Major Shift in Generic Drug Manufacturing: DelveInsight Projects $310 Billion API Market Opportunity by 2030
FDA's New ANDA Prioritization Pilot Signals Major Shift in Generic Drug Manufact …
The U.S. Food and Drug Administration's announcement of its groundbreaking ANDA Prioritization Pilot program on October 3, 2025, represents a paradigm shift in generic drug manufacturing that will significantly impact the global Active Pharmaceutical Ingredients (API) market, according to DelveInsight Business Research LLP, a leading pharmaceutical market intelligence firm. The FDA's announcement of ANDA Prioritization Pilot program offers expedited review pathways for generic drug manufacturers who conduct bioequivalence testing in the

All 5 Releases


More Releases for Kaine

Technology Integration Group Founder Co-Chairs USPACC CelebrAsian Procurement Op …
FOR IMMEDIATE RELEASE Technology Integration Group Founder Co-Chairs USPACC CelebrAsian Procurement Opportunity Conference San Diego, CA - June 12, 2014 - Bruce Geier, CEO and Founder of Global IT solutions integrator Technology Integration Group (TIG) co-chairs 29th annual US Pan Asian American Chamber of Commerce Education Foundation (USPACC) - CelebrAsian Procurement Opportunity Conference. United States Senator from the Commonwealth of Virginia, The Honorable Timothy Kaine welcomed over 700 conference participants – representing more
CSC to Move Corporate Headquarters to Virginia
New Delhi, February 4, 2008 - Computer Sciences Corporation (NYSE: CSC) announced that its Board of Directors has approved a decision to relocate corporate headquarters to Falls Church, Va., from El Segundo, Calif. The relocation will consolidate into one geographical location the corporate executive leadership with the company's global operational headquarters. The consolidation will achieve enhanced productivity by reducing extensive travel now required between the two locations, facilitate the frequency